# PODD — Insulet · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** PODD  
**Sources:** 29  
**Published:** 2026-08-03  
**Canonical:** https://app.k3vl4r.com/research/deep-research-podd-insulet-catalysts-narrative-risks-583

---

# Insulet Corporation (PODD) — Research Summary as of August 3, 2026

## Company Overview

Insulet Corporation (NASDAQ: PODD) is a medical device company headquartered in Acton, Massachusetts, founded in 2000. It develops, manufactures, and sells insulin delivery systems — most notably the Omnipod platform — for people with insulin-dependent diabetes [[25]](https://investor.insulet.com/overview/default.aspx)[[22]](https://seekingalpha.com/symbol/PODD). As of August 2, 2026, the stock traded at approximately $165.35 with a market capitalization of $11.57 billion and a P/E ratio of 38.49 [[14]](https://robinhood.com/us/en/stocks/PODD/).

---

## Key Recent Catalysts (Last ~1–3 Months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-podd-insulet-catalysts-narrative-risks-583 (free to sign up)._